medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2012, Number 3

<< Back Next >>

Salud Mental 2012; 35 (3)

Perimenopausia y trastornos afectivos: aspectos básicos y clínicos

Flores RM, Martínez ML

Language: Spanish
References: 84
Page: 231-240
PDF size: 325.86 Kb.


ABSTRACT

Depression is an affective disorder that is more frequent in women than men. The etiology of depression disorders is multi-factorial, since social and biological influences have been determined. Coincidence between periods with hormonal fluctuations and affective alterations has lead to a hypothesis that considers fluctuations in gonadal hormones as a possible cause of depression in women. In this respect, pre-clinical studies by using laboratory animals (rodents) point toward a stronger relationship between hormonal oscillations and depressive behavior in different models designed to evaluate the antidepressant effect of drugs. This evidence could be interesting since in pre-clinical studies social factors are not included.
Specifically, several authors have reported that depressive behavior is more prevalent in stages of rats’ life characterized by low concentrations of gonadal hormones, such as postpartum, diestrous phase, lactancy and after ovariectomy. In contrast, a major presence of depressive behavior is observed in phases with higher concentration of hormones, like proestrus (a phase coincident with ovulation), pregnancy and after hormonal restitution with estrogens and progestins. Interestingly, the development of depressive behavior after ovariectomy has been established in female mice, with a critical period 12 weeks after ovaries extirpation.
The participation of specific hormones in female depression could be studied in lab animals, since rodent female progress from a reproductive to a non-reproductive phase with vaginal and endocrine changes. Young females have a 4-5 days cycle named estrous cycle, in which each vaginal phase is associated with different concentrations of gonadal hormones. Although rodents do not exhibit menses, a state similar to peri- and post-menopause could be identified. Aging females exhibit irregular cycles before progressing to an estrous constant phase with elevated levels of estrogens. Decline of estrogen levels produces a persistent diestrous phase considered as a postmenopausal state. Aging rats in persistent diestrous, as well as ovariectomized females (the most economic model of post-menopause in lab animals) show physiological and behavioral changes associated to hormonal deprivation. Thus, they are considered a good model to evaluate affective and cognitive alterations as well as potential hormonal substitutive treatments.
Clinical and epidemiologic studies report that perimenopause is linked to an increased risk of developing depression in women, or with the presence of more intense symptoms of depression. In agreement with Stages of Reproductive Aging Workshop (STRAW), perimenopause includes the period named transition to menopause plus one year after the last menses. This period is characterized by irregular menstrual cycles and fluctuations in levels of estrogens. In this stage, the levels of follicle-stimulating hormone (FSH) are elevated in order to further stimulate the production of estrogens from ovaries. Finally, concentrations of estrogens are significantly reduced in late perimenopause, although the levels of FSH continue to be increased. Fluctuations of estrogens and FSH have been related to symptoms such as affective alterations, hot flushes and insomnia, while hormonal deprivation in post-menopause is linked to changes in body fat, fatigue, cognitive disorders and reduction in bone density. Variations in estrogens and FSH level have been consistently related to depression symptoms in perimenopausal women, while changes in progestins and testosterone are associated with dysphoric mood and aggression, respectively. Thus, in agreement with the main hormonal hypothesis, a substitutive therapy with estrogens as an antidepressant therapy in peri- and post-menopausal women has been implemented. The results of different clinical studies are contradictory possibly due to methodological differences as the type of hormone used as an antidepressant therapy, dosage, time of administration of treatments and the period of hormonal deprivation in women.
In a consistent manner, basic studies support the idea that steroidal gonadal hormones have antidepressant properties, but these seem to depend on both specific features of hormonal treatments and endocrine conditions in females. It has been reported that 17β-estradiol (E2), ethinyl-estradiol (EE2) and estradiol benzoate produce antidepressant- like actions in ovariectomized young females. Pharmacological studies have demonstrated that the serotonergic system has a major participation in the antidepressant-like effect of E2, revealing its potential as a treatment for depressed women. In the same sense, estrogens that bind to estrogen receptors β (ERβ) are more effective to produce antidepressant- and anxiolytic-like effects than estrogens with higher affinity at ERα This evidence leads to consider ERβ as an important pharmacological target in depression.
Studies evaluating estrogens in depression have determined that dosage is an important issue in the production of antidepressant-like effects. Dosage of estrogens that attain a physiological range have been reported to have more antidepressant efficacy in respect to lower or higher dose provoking infra- or supra-physiological levels of estradiol. In fact, a U-shape in the antidepressant effect of E2 has been detected.
Finally, timing of hormonal therapy seems to be a more relevant factor at moment to attain an antidepressant effect with estrogen treatment. Old rats (14 months) that received a prolonged estrogen treatment immediately after ovariectomy showed an antidepressant-like response which was not observed when treatment was began five months after ovaries extirpation. ERs are dependent on endogenous estrogens levels which suggest that a reduction in the target site of E2 may be linked to its reduced antidepressant-like effect in females with a long-term hormonal deprivation.
An apparently successful strategy to reduce depression in women has been to adjunct a hormonal treatment with antidepressant drugs in order to enhance antidepressant efficacy. Studies with a reduced number of patients have determined that combined therapy is able to reduce the scores in the Hamilton Depression Scale, and to allow the effect of antidepressant drugs in women with refractory depression. At this respect, basic studies have established that estrogens facilitate the antidepressant effects of several antidepressant drugs. It was reported that the anxiolytic effect of desipramine was more evident in the proestrus, a phase characterized by high levels of estrogens and progesterone in young females. Both estrogens and progesterone participate in the anxiolytic effect of desipramine, although the synergism with estradiol was more significant. By using specific animal models of antidepressant effects, it was found that E2 facilitated the antidepressant effect of fluoxetine, desipramine, venlafaxine and bupropion in young, ovariectomized female rodents. In contrast, a chronic study using old, ovariectomized female rats showed that estradiol valerate was unable to improve the antidepressant effect of citalopram, even though the antidepressant efficacy of both estrogen and citalopram was established previously. Differences in results could be due to variations in methodological aspects such as age of rats (young, three months, versus old, 15 month), type of estrogen used in each study (E2 versus estradiol valerate), animal model of depression (forced swimming test, acute model, versus chronic mild stress model), type of antidepressant used (citalopram in the last case), and dosage for both estrogens and antidepressant drugs. Interestingly, the strategy of a combined treatment could be a therapeutic advantage for those women that suffer depression associated to endocrine changes. Evidence from clinical and basic studies should be taken into account at moment to select the most advantageous therapy to treat depression in mature women.


REFERENCES

  1. Wise PM. Neuroendocrine correlates of aging. En: Conn PM, Freeman ME (eds.). Neuroendocrinology in physiology and medicine. Totowa, NJ: Human Press Inc.; 2000; pp. 371-387.

  2. Wu JM, Zelinski MB, Ingram DK, Ottinger MA. Ovarian aging and menopause: current theories, hypotheses and researches models. Exp Biol Med 2005;230:818-828.

  3. Lemini C, Canchola E. Effects of 17β-aminoestrogens on the sexual behavior of female rats. Physiol Behav 2009;96(4-5):662-666.

  4. Bernardi M, Vergoni AV, Sandrini M, Taglianini S et al. Influence of ovariectomy, estradiol and progesterone on the behavior of mice in an experimental model of depression. Physiol Behav 1989;45:1067-1068.

  5. Shors TJ, Leuner B. Estrogen-mediated effects on depression and memory formation in females. J Affect Disord 2003;71(1):85-96.

  6. Bekku N, Yoshimura H, Araki H. Factors producing a menopausal depressive-like state in mice following ovariectomy. Psychopharmacology 2006;187(2):170-180.

  7. Bekku N, Yoshimura H. Animal model of menopausal depressive-like state in female mice: prolongation of immobility time in the forced swimming test following ovariectomy. Psychopharmacology 2005;183(3):300-307.

  8. Picazo O, Estrada-Camarena E, Hernández-Aragón A. Influence of the post-ovariectomy time frame on the experimental anxiety and the behavioral actions of some anxiolytic agents. Eur J Pharmacol 2006;530(1- 2):88-94.

  9. Anisman H, Matheson K. Stress, depression and anhedonia: caveats concerning animal models. Neurosci Biobehav Rev 2005;29(4-5):525-546.

  10. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural- neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52:90-110.

  11. Porsolt R, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266:730-732.

  12. Detke M, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995;121:66-72.

  13. Frye C, Walf A. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Horm Behav 2002;41:306-315.

  14. Contreras C, Martínez-Mota L, Saavedra M. Desipramine restricts estral cycle oscillations in swimming. Prog Neuropsychopharmacol Biol Psychiat 1998;22:1121-1128.

  15. Contreras CM, Molina M, Saavedra M, Martínez-Mota L. Lateral septal neuronal firing increases during proestrus-estrus in the rat. Physiol Behav 2000;68(3):279-284.

  16. Molina-Hernández M, Téllez-Alcántara NP. Antidepressant-like actions of pregnancy, and progesterone in Wistar rats forced to swim. Psychoneuroendocrinology 2001;26(5):479-491.

  17. Dalla C, Antoniuo K, Droussopoulou G, Xagoraris M et al. Chronic mild stress impact: are female more vulnerable? Neuroscience 2005;135:703-714.

  18. Walf AA, Paris JJ, Frye CA. Chronic estradiol replacement to aged female rats reduces anxiety-like and depression-like behavior and enhances cognitive performance. Psychoneuroendocrinology 2009;34(6):909-916.

  19. Walf AA, Madeleine ER, Frye CA. Antidepressant effects of ERβ-selective estrogen receptor modulators in the forced swimming test. Pharmacol Biochem Behav 2004;78:52.

  20. Rachmann IL, Unnerstall JR, Pfaff DW, Cohen RS. Estrogens alter behavior and forebrain cfos expression in ovariectomized rats subjected to de forced swim test. Proc Natl Acad Sci 1998;95:13941-13946.

  21. Estrada-Camarena E, Fernández-Guasti A, López-Rubalcava C. Interaction between estrogens and antidepressants in the forced swimming test in rats. Psychopharmacology 2004;173:139-145.

  22. Rodríguez-Landa JF, Contreras CM, Bernal-Morales B, Gutiérrez-García AG et al. Allopregnanolone reduces immobility in the forced swimming test and increases the firing rate of lateral septal neurons through actions on the GABAA receptor in the rat. J Psychopharmacol 2006;21(1):76-84.

  23. Fernández-Guasti A, Picazo O. Flumazenil blocks the anxiolytic action of allopregnanolone. Eur J Pharmacol 1995;281:113-115.

  24. Urani A, Roman FJ, Phan VL, Su TP et al. The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001;298(3):1269-1279.

  25. Frye CA, Rodhes ME, Petralia SM, Walf AA et al. 3α-Hydroxy-5α-pregnan- 20-one in the midbrain ventral tegmental area mediates social, sexual, and affective behaviors. Neuroscience 2006;138(3):1007-1014.

  26. Barbaccia ML, Roscetti G, Trabucci M, Mostalino MC et al. Time-dependent changes in rat brain neurooactive steroid concentrations and GABA receptor function after acute stress. Neuroendocrinology 1996;63:166-172.

  27. Genazzani AR, Monteleone P, Gambacciani M: Hormonal influence on the central nervous system. Maturitas 2002;43(1):S11-S17.

  28. Ciriza I, Carrero P, Frye CA, García-Segura LM. Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestine medroxyprogesterone acetate (Provera) is not neuroprotective. J Neurobiol 2006;66(9):916-928.

  29. Estrada-Camarena E, Fernández-Guasti A, López-Rubalcava C. Facilitating antidepressant-like actions of estrogens are mediated by 5-HT1A and estrogen receptors in the rat forced swimming test. Psychoneuroendocrinology 2006;31(8):905-914.

  30. Estrada-Camarena E, Rivera NM, Berlanga C, Fernández-Guasti A. Reduction in the latency of action of antidepressants by 17β-estradiol in the forced swimming test. Psychopharmacology 2008;201(3):351-360.

  31. Yamaguchi-Shima N, Yuri K. Age-related changes in the expression of ER-beta mRNA in the female rat brain. Brain Res 2007;1155:34-41.

  32. Walf AA, Ciriza I, García Segura LM, Frye CA. Antisense oligodeoxynucleotides for estrogen receptor-beta and alpha attenuate estradiol’s modulation of affective and sexual behavior, respectively. Neuropsychopharmacology 2008;33(2):431-440.

  33. Walf AA, Madeleine ER, Frye CA. Antidepressant effects of ERβ-selective estrogen receptor modulators in the forced swimming test. Pharmacol Biochem Behav 2004;78:52.

  34. Walf AA, Frye C. Antianxiety and antidepressive behavior produced by physiological estradiol regimen may be modulated by hypothalamic- pituitary-adrenal axis activity. Neuropsychopharmacology 2005;30(7):1288-1301.

  35. Estrada-Camarena E, Fernández-Guasti A, López-Rubalcava C. Antidepressant- like effect of different estrogenic compounds in the forced swimming test. Neuropsychopharmacology 2003;28:830-838.

  36. Fernández-Guasti A, Martínez-Mota L, Estrada-Camarena E, Contreras CM et al. Chronic treatment with desipramine induces an estrous-cycle dependent anxiolytic-like action in the burying Behavior, but not in the elevated plus maze. Pharmacol Biochem Behav 1999;63(1):13-20.

  37. Martínez-Mota L, Estrada-Camarena E, López-Rubalcava C, Contreras CM. Interaction of desipramine with steroid hormones on experimental anxiety. Psychoneuroendocrinology 2000;25(2):109-120.

  38. Dhir A, Kulkarni SK. Antidepressant-like effect of 17beta-estradiol: involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor system. Can J Physiol Pharmacol 2008;86(10):726-735.

  39. Rossi DV, Burke TF, McCasland M, Hensler JG. Serotonin-1A receptor function in the dorsal raphe nucleus following chronic administration of the selective serotonin reuptake inhibitor sertraline. J Neurochem 2008;105(4):1091-1099.

  40. Raap D, DonCarlos L, García F, Muma N et al. Estrogen desensitizes 5-HT1A receptors and reduces levels of Gz,Gi1 and Gi3 proteins in the hypothalamus. Neuropharmacology 2000;39:1823-1832.

  41. Romano-Torres M, Fernández-Guasti A. Estradiol valerate elicits antidepressant-like effect in middle-aged female rats under chronic mild stress. Behav Pharmacol 2010;21:104-111.

  42. Belló M, Puentes-Rosas E, Medina-Mora ME. Prevalencia y diagnóstico de depresión en población adulta en México. Salud Pública Mex 2005;47(1):4-11.

  43. Kessler RC. Epidemiology of women and depression. J Affect Disord 2003;74:5-13.

  44. Weissman MM, Bland RC, Canino GJ. Cross-national epidemiology of major depression and bipolar disorder. J Am Med Assoc 1996;276:293-299.

  45. Halbreich U. Women´s reproductive related disorders (RRDs). J Affect Disord 2010;122(1-2):10-13.

  46. Backstrom T, Andersson A, Andre L. Pathogenesis in menstrual cyclelinked CNS disorders. Ann N Y Acad Sci 2003;1007:42-53.

  47. Bancroft J, Cook A, Davidson D. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with premenstrual mood change. Psychol Med 1991;21:305-312.

  48. Henshaw C. Mood disturbance in the early puerperium: a review. Arch W Ment Health 2003;6:S33-S42.

  49. Josefsson A, Berg G, Nordin C. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001;80:251-255.

  50. Pearlstein T, Howard M, Salisbury A. Postpartum depression. Am J Obstet Gynecol 2009;200(4):357-364.

  51. Soules MR, Sherman SH, Parrot E. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001;76(5):874-878.

  52. Santoro N, Brown J, Adel T. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495-1501.

  53. Morrison JH, Brinton RD, Schmidt PJ. Estrogen, menopause and the aging brain: how basic neuroscience can inform hormone therapy in women. J Neurosci 2006;26:10332-10348.

  54. Rasgon N, Shelton S, Halbreich U. Perimenopausal mental disorders: Epidemiology and Phenomenology. CNS Spectrums 2005;10(6):471-478.

  55. Burger HG, Dudley EC, Robertson DM. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-275.

  56. Yamada M, Soda M, Fujiwara S. Follicle-stimulating hormone and oestradiol levels during perimenopause in a cohort of Japanese women. Int J Clin Pract 2008;62(10):1623-1627.

  57. Bromberger JT, Meyer PM, Kravitz HM. Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health 2001;91:1435-1442.

  58. Yen JY, Yang MS, Wang MH. The associations between menopausal syndrome and depression during pre-, peri-, and post-menopausal period among Taiwanese female aborigines. Psychiat Clin Neurosci 2009;junio(abstract);30.

  59. Slaven L, Lee C. Mood and symptom reporting among middle-aged women: the relationship between menopausal status, hormone replacement therapy, and exercise participation. Health Psychol 1997;16:203-208.

  60. Juang KD, Wang SJ, Lu SR. Hot flashes are associated with psychological symptoms of anxiety and depression in peri- and post- but no premenopausal women. Maturitas 2005,52:119-126.

  61. Woods NF, Mariella A, Mitchell ES. Depressed mood symptoms during the menopausal transition: observations from the Seattle Midlife Women´s Health Study. Climacteric 2006;9:195-203.

  62. Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004;161(12):2238-2244.

  63. 63.Freeman EW, Sammel MD, Liu L. Hormones and menopausal status as predictors of depression in women transition to menopause. Arch Gen Psychiat 2004;61:62-70.

  64. Marteens LWF, Knottnerus JA, Pep VJ. Menopausal transition and increased depressive symptomatology: a community based prospective study. Maturitas 2002;42:195-2002.

  65. Cohen LS, Soares CN, Vitonis A. Risk for new onset of depression during the menopausal transition. Arch Gen Psychiat 2006;63:385-390.

  66. Woods NF, Smith-DiJulio K, Percival DB. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women´s Health Study. Menopause 2008;15(2):223-232.

  67. Soares CN. The menopausal transition and depression : a window of vulnerability? Menopause Management 2008;marzo/abril:12-25.

  68. Soares CD, Almeida OP, Joffe H. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double blind, randomized, placebo-controlled trial. Arch Gen Psychiat 2001;58:529-534.

  69. Stahl SM. Augmentation of antidepressant by estrogen. Psychopharmacol Bull 1998;34(3):319-321.

  70. Feld J, Halbreich U, Karkun S. The association of perimenopausal mood disorders with other reproductive- related disorders. CNS Spectrums 2005;10(6):461-470.

  71. Young EA, Rees Midgley A, Carlson NE. Alteration in the hypothalamic-pituitary-ovarian axis in depressed women. Arch Gen Psychiat 2000;57:1157-1162.

  72. Schmidt PJ, Murphy JH, Danaceau MA. Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology 2002;27(8):907-920.

  73. 73 Freeman EW, Sammel MD, Lin H. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiat 2006;63:375-382.

  74. Daly R, Danaceau M, Rubinow D. Concordant restoration of ovarian function and mood in perimenopausal depression. Am J Psychiat 2003;160: 1842-1846.

  75. Rajewska J, Rybakowsky J. Depression in premenopausal women: gonadal hormones and serotonergic system assessed by D-fenfluramine challenge test. Prog Neuro-Psychopharmacol Biol Psychiat 2003;27:705-709.

  76. Ryan J, Burger HG, Szoeke C. A prospective study of the association between endogenous hormones and depressive symptoms in postmenopausal women. Menopause 2009;16(3):509-517.

  77. Rohr UD. The impact of testosterone imbalance on depression and women´s health. Maturitas 2002;41(1):S25-S46.

  78. Stoppe G, Dören M. Critical appraisal of effects of estrogen replacement therapy on symptoms of depressed mood. Arch Womens Ment Health 2002;5:39-47.

  79. Schmidt PJ, Roca C, Rubinow DR. Clinical evaluation in studies of perimenopausal women: Position paper. Psychoparmacol Bull 1998;34(3):309-311.

  80. Soares CD, Almeida OP, Joffe H. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double blind, randomized, placebo-controlled trial. Arch Gen Psychiat 2001;58:529-534.

  81. Schmidt PJ, Nieman L, Danaceau MA. Estrogen replacement in perimenopause- related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-420.

  82. Rasgon N, Altshuler LL, Fairbanks LA. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiat 2002;63(Supl. 7):45-48.

  83. Morgan ML, Cook IA, Rapkin AJ. Estrogen augmentation of antidepressant in perimenopausal depression: a pilot study. J Clin Psychiat 2005;66(6):774-780.

  84. Dias RS, Kerr-Correa F, Moreno RA. Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. Menopause 2005;13(2):168-170.




2020     |     www.medigraphic.com